Physician profile
Mark A Mclaughlin
NPI 1972552438
$6,551.36
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,744 · 2020: $1,793 · 2021: $2,295 · 2022: $720.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $941.12 | 2019-2021 | |
| Amgen INC. | $560.02 | 2019-2022 | |
| Amarin Pharma, INC. | $556.80 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $524.99 | 2019-2022 | |
| Pfizer INC. | $485.57 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $448.29 | 2019-2021 | |
| Novo Nordisk INC | $343.57 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $294.37 | 2019-2022 | |
| Abbvie INC. | $211.89 | 2021-2022 | |
| Allergan, INC. | $174.64 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.57 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $153.91 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $148.26 | 2020-2022 | |
| Lilly USA, LLC | $132.97 | 2019-2022 | |
| Esperion Therapeutics, INC. | $123.73 | 2021 |
Show all 43 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.